The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLVI.a

Pulmonary embolism - Venous thrombosis/thromboembolism

Publications

Cui X, Wan Z, Ma Z, Liu L, Yang Y

Occurrence of acute pulmonary embolism induced by recombinant erythropoietin during treatment of pure red cell aplasia associated with thymoma: A case report.

Medicine 2019 Mar;98;e14789 — 2019 Mar — e14789

Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI

Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.

Journal of the National Cancer Institute 2009 Dec 02;101;1633-41 — 2009 Dec 02 — 1633-41

Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

JAMA 2008 Feb 27;299;914-24 — 2008 Feb 27 — 914-24